查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1560205

类毒素疫苗市场报告：2030 年趋势、预测与竞争分析

Toxoid Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

类毒素疫苗趋势与预测

到 2030 年，全球类毒素疫苗市场预计将达到 75 亿美元，2024 年至 2030 年复合年增长率为 4.5%。该市场的主要驱动因素包括感染疾病爆发的增加、新兴市场疫苗接种需求的增加以及政府鼓励疫苗接种的支持措施。全球类毒素疫苗市场的未来充满希望，医院、专业机构和政府市场都充满机会。

Lucintel 预测，由于儿童使用 DTaP 来保护自己免受白喉、破伤风和百日咳等危险疾病的影响，DTaP 在预测期内将出现最高增长。

在这个市场中，由于医院类毒素疫苗接种的增加，尤其是针对婴幼儿和孕妇的类毒素疫苗接种，预计医院在预测期内将出现最高增长。由于人口快速增长和感染疾病患者数量不断增加，预计亚太地区在预测期内将出现最高的增长。

类毒素疫苗市场的新趋势

类毒素疫苗市场正在见证许多新兴趋势，包括技术进步、公共卫生优先事项的变化以及疾病概况的变化。这些变化正在影响类毒素疫苗的开发和部署的未来，从而影响市场动态和健康结果。

  • 组合疫苗的优势日益增强：预防多种疾病的组合类毒素疫苗的开发正在取得进展。这种方法简化了疫苗接种计划并提高了公共卫生效率。白喉、破伤风和百日咳的联合疫苗变得越来越普遍，因为它提供了全面的保护。
  • 佐剂技术的进步：正在开发新的佐剂来增强类毒素疫苗的免疫反应。这些改进旨在提高疫苗的有效性，同时减少所需的注射次数。创新佐剂为疫苗带来更强、更持久的免疫力。
  • 扩大疫苗的取得范围：低收入国家正在加强扩大类毒素疫苗的取得范围。为了缩小发展中国家和富裕国家在医疗保健服务方面的差距并加速全球免疫工作，全球卫生倡议与伙伴关係关係一道，正在努力改善疫苗的分发，重点是提高负担能力并惠及不符合条件的人群用于疫苗接种。
  • 改进配方的开发：对新疫苗配方的研究仍在继续，重点是提高安全性和有效性。这包括开发副作用较少的疫苗和改善对特定疾病菌株的保护，从而提高疫苗的整体表现。
  • 数位健康技术的整合：该过程包括将数位健康技术整合到疫苗监测和管理中。这包括使用电子健康记录和行动应用程式来追踪疫苗接种计划、管理不利事件和提高患者依从性，从而实现高效的疫苗接种计划。

这些趋势正在改变我们对类毒素疫苗市场的看法，推动创新和增加可及性，同时提高疫苗功效。最终，这将透过更好的疫苗开发和部署程序（包括技术等其他领域）来改善公共卫生结果。

类毒素疫苗市场的最新趋势

类毒素疫苗市场的最新发展反映了疫苗技术、生产和公共卫生策略的显着增强。类毒素疫苗可以解决各种健康问题，并且正在提高全世界疫苗的有效性和可近性。

  • 新疫苗配方的增强：此外，正在开发类毒素疫苗的新配方，包括先进的佐剂以及改进的输送系统，以提高功效，同时减少副作用。这些创新旨在提高疫苗的安全性能。
  • 提高生产能力：疫苗生产设施的扩建和技术的改进正在增加类毒素疫苗的可用性。这涉及改进製造流程以及增加产量以满足不断增长的需求。
  • 围绕疫苗取得的政府措施：世界各国政府正在投资疫苗研究并实施公共卫生计划，以提高免疫接种的水平。这些倡议的重点是改善疫苗的分发、可负担性和可近性，特别是对于生活在服务不足地区的人们。
  • 合作研发：製药公司、研究机构和政府机构之间不断加强的合作正在推动类毒素疫苗的创新。因此，此类合作伙伴关係正在加速新疫苗的开发并增强这些产品的旧版本。
  • 关注疫苗安全性：因此，正在进行的研究旨在提高类毒素疫苗的安全性和有效性。这些研究也旨在提供有关疫苗接种相关副作用的知识，同时改善整体免疫工作。

最近的这些变化对类毒素疫苗市场产生了重大影响，推动了新颖性、提高了产量并扩大了可用性。这是疫苗技术和公共卫生策略进步的结果，可以更好地预防疾病并改善健康结果。

类毒素疫苗市场的策略性成长机会

类毒素疫苗市场在多种应用领域拥有众多策略性成长机会。这些机会源自于疫苗技术的进步、疾病盛行率的增加、公共卫生需求的改变。

  • 感染疾病预防：针对白喉、破伤风和百日咳等感染疾病的类毒素疫苗的开发带来了巨大的成长机会。扩大疫苗接种覆盖率并改善这些疾病的疫苗接种方案可以改善公共卫生状况，同时预防疫情爆发。
  • 小儿科免疫 类毒素疫苗在儿科免疫计划中存在巨大的成长机会。透过开发联合疫苗来简化儿童疾病的免疫接种计划，可以有效应对儿童常见疾病并提高覆盖率。
  • 旅行者健康：透过向旅行者註射类毒素疫苗，重点关注特定地区和旅行者中流行的疾病，可以获得成长机会。开发广泛保护国际旅客的疫苗可以支持全球卫生倡议并改善预期的健康结果。
  • 老年人健康：老年人面临破伤风等疾病的风险，是类毒素疫苗开发的潜在市场。这些疫苗应专门为老年人设计，以改善该年龄层的疾病预防和健康状况。

因此，这些机会透过刺激技术创新和扩大应用领域来塑造类毒素疫苗市场。有效抓住这些机会的公司不仅可以从市场扩张中受益，还可以为改善公共卫生做出贡献。

类毒素疫苗市场驱动因素与挑战

各种技术、经济和监管因素影响类毒素疫苗市场。了解这些驱动因素和问题对于驾驭市场并寻求业务成长机会至关重要。

类毒素疫苗市场的驱动因素包括：

1. 技术进步：技术进步：佐剂和递送系统的改进有助于疫苗技术的扩展。这些突破将提高疫苗的效率和安全性，同时解决新的公共卫生优先事项。

2.疾病增加：由于白喉、破伤风等疾病的流行增加，类毒素疫苗的需求增加。因此，开发有效的疫苗来应对这些对公共卫生和疾病预防的威胁非常重要。

3. 政府投资：市场成长受到政府在疫苗研究、製造和公共卫生计画的高支出的支持。这就是为什么要提供资金来提高疫苗的可用性、可负担性和覆盖率。

4. 全球卫生工作：国际合作和卫生保健工作正在改善类毒素疫苗的取得。这也包括旨在改善疫苗接种方式和解决健康差异以帮助开拓市场的计划。

5. 关注疫苗安全性：提高疫苗安全性的研究将决定当今市场趋势的方向。因此，接种安全有效的疫苗将增强人们接种疫苗的信心，促进疫苗接种。

类毒素疫苗市场面临的挑战包括：

1. 高昂的开发成本：製造类毒素疫苗需要研究、临床试验和製造成本。价格过高，可能限制市场进入。

2. 监管障碍：疫苗开发可能会受到严格的监管要求，并因核准流程而延误。这并不容易，但必须符合安全标准。

3.供应链问题：任何扰乱疫苗供应链的因素，从原料短缺到生产延误，都会影响疫苗的供应和分配。

类毒素疫苗市场受到技术进步、发病率上升和大规模投资的影响。然而，维持市场成长和稳定仍存在许多挑战，包括高昂的开发成本、监管障碍和供应链问题。

类毒素疫苗按市场

本研究按疫苗类型、最终用途和地区对全球类毒素疫苗进行了预测。

类毒素疫苗市场前景（依国家划分）

在疫苗技术、疾病控制策略和公共卫生计画进步的支持下，类毒素疫苗产业在关键地区正在经历显着成长。美国、中国、德国、印度和日本的最新进展反映了全球为提高类毒素疫苗的有效性和可及性以创新应对各种健康挑战所做的努力。

  • 美国：在美国，针对白喉和破伤风等疾病的混合毒力疫苗已取得突破。疫苗配方和输送系统的创新提高了疫苗功效，同时确保患者遵守规定剂量。除此之外，美国还注重公共卫生计划的可及性并确保全国范围内提供最新的有毒疫苗。
  • 中国 中国在开发白喉、破伤风、百日咳等疾病的类毒素疫苗方面取得了显着进展。这包括提高疫苗生产能力和进行临床试验以提高疫苗有效性。中国政府正大力投资疫苗研究和公共卫生基础设施，扩大疫苗接种覆盖范围，同时解决与疫苗相关的新健康问题。
  • 德国 德国类毒素疫苗研究正在取得进展，以期提高疫苗的安全性和有效性。德国强大的法律规范，加上製药公司和研究机构之间的密切合作，支持类毒素疫苗的创新研发。
  • 印度 印度类毒素疫苗的可及性和可负担性方面最近取得的进展归功于各相关人员的努力。除了提高类毒素疫苗的生产能力外，我们也正在开发针对破伤风和白喉等疾病的新疫苗。这主要是透过政府措施以及与国际组织的合作来确保更多印度人接种疫苗而实现的。
  • 日本 在日本，类毒素疫苗的开发正在取得进展，并正在努力改进疫苗的製造方法和安全性。最近，关于新佐剂和递送系统的研究不断取得进展，以提高疫苗的有效性。日本类毒素疫苗的开发是由政府机构与 Pharmacology 等私人公司之间的合作所推动的。

常问问题

Q.1 类毒素疫苗的市场规模有多大？

A1. 到 2030 年，全球类毒素疫苗市场预计将达到 75 亿美元。

Q.2 类毒素疫苗市场的成长预测如何？

A2. 2024年至2030年，全球类毒素疫苗市场预计将以4.5%的复合年增长率成长。

Q.3 影响类毒素疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是感染疾病爆发数量的增加、新兴市场疫苗接种需求的增加以及政府鼓励疫苗接种的支持措施。

Q4.市场的主要细分市场是：

A4. 类毒素疫苗市场前景广阔，在医院、专业机构和政府市场都有机会。

Q5.市场的主要企业是：

A5. 生产类毒素疫苗的主要企业如下：

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Q6. 未来类毒素疫苗的最大市场区隔会是哪一个？

A6.Lucintel 预测 DTaP 在预测期内将出现最高增长，因为它越来越多地在儿童中使用，以预防白喉、破伤风和百日咳等危险疾病。

Q7. 未来五年类毒素疫苗市场预计成长最快的是哪个地区？

A7.由于人口快速增长和感染疾病患者数量不断增加，预计亚太地区在预测期内将出现最高增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球类毒素疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球类毒素疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 按疫苗类型分類的全球类毒素疫苗市场
    • 白喉、破伤风、百日咳 (DTaP)
    • 白喉和破伤风 (DT)
    • 破伤风、白喉和百日咳 (TDaP)
    • 其他的
  • 全球类毒素疫苗市场（依最终用途）
    • 医院
    • 专业中心
    • 政府组织
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球类毒素疫苗市场（按地区）
  • 北美类毒素疫苗市场
  • 欧洲类毒素疫苗市场
  • 亚太类毒素疫苗市场
  • 其他区域类毒素疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按疫苗类型分類的全球类毒素疫苗市场成长机会
    • 全球类毒素疫苗市场成长机会（依最终用途）
    • 全球类毒素疫苗市场成长机会（按地区）
  • 全球类毒素疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球类毒素疫苗市场产能扩张
    • 全球类毒素疫苗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Bharat Biotech
  • Ceva
    • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent BioSolutions
  • Integrated Biotherapeutics
  • Abbott
简介目录

Toxoid Vaccine Trends and Forecast

The future of the global toxoid vaccine market looks promising with opportunities in the hospital, specialty centre, and government organization markets. The global toxoid vaccine market is expected to reach an estimated $7.5 billion by 2030 with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are rising prevalence of infectious diseases, augmenting demand for vaccination in developing countries, and supportive initiatives by the government to encourage immunization.

Lucintel forecasts that DTaP is expected to witness the highest growth over the forecast period due to its growing usage among children to protect against the dangerous illnesses of diphtheria, tetanus, and pertussis.

Within this market, the hospital is expected to witness the highest growth over the forecast period due to the growing number of toxoid vaccinations given out in hospitals, particularly to infants and pregnant women. APAC is expected to witness the highest growth over the forecast period due to the rapid population growth and the rising cases of infectious illnesses among people in the region.

Emerging Trends in the Toxoid Vaccine Market

The toxoid vaccine market is witnessing numerous emerging trends that demonstrate advancements in technology, shifting priorities of public health, and changing disease profiles. These changes are influencing the future of toxoid vaccine development and deployment, with consequent impacts on market dynamics as well as health outcomes.

  • Rising Advantage of Combination Vaccines: There is a movement towards the development of more combination toxoid vaccines meant to protect from several diseases. This approach simplifies immunization schedules and enhances public health efficiency. Combination vaccines for diphtheria, tetanus, and pertussis are becoming more common because they provide all-inclusive coverage.
  • Advances in Adjuvant Technologies: New adjuvants are being developed to boost the immune response of toxoid vaccines. These improvements aim at increasing vaccine effectiveness while reducing number of doses required. Innovative adjuvants introduce to vaccines stronger immunity over a longer period.
  • Vaccine Access Expansion: Efforts aimed at expanding access to toxoid vaccines have been increased in low income countries. Global initiatives for health in conjunction with partnerships focus on improving the distribution, affordability and reaching out those not covered by vaccination interventions across the world in order to reduce disparities in health care provision between developing nations and rich countries that also encourages worldwide immunization efforts.
  • Development of Improved Formulations: Research on the new vaccine formulations is advancing with focus on improving safety and efficacies. This includes development of vaccines with limited side effects and improved protection for certain strains of diseases leading to better overall vaccine performances.
  • Integration of Digital Health Technologies: The process involves integration of digital health technologies into vaccine monitoring and management. They entail use of electronic health records, mobile apps used in tracking vaccination schedules, managing adverse events and improving patient adherence thus leading to efficient vaccination programs.

These trends are changing how we think about toxoid vaccine market by encouraging innovation while improving on the efficacy of vaccines as well as increasing access. Ultimately, this is enhancing public health outcomes through better development and deployment procedures for vaccines that now encompass other areas like technology.

Recent Developments in the Toxoid Vaccine Market

Recent developments in the toxoid vaccine market reflect significant enhancements in vaccine technology, production, and public health strategies. They are addressing different health problems and improving global vaccine efficacy and accessibility.

  • New Enhanced Vaccine Formulations: Besides, newer formulations for toxoid vaccines are being developed which include advanced adjuvants as well as improved delivery systems to improve their effectiveness while reducing side effects. Such innovations aim at enhancing the performance of vaccines with regards to safety profiles.
  • Increased Production Capacities: by expanding vaccine production facilities and upgrading technology this has led to an increase in toxoid vaccines availability. This entails improvements in the manufacturing processes alongside a scale-up of the output to cater for a growing demand.
  • Government Initiatives on Vaccine Access: Governments across the world spend money in research on vaccines and maintain public health programs that will help them widen access levels of these vaccinations. The focus of these initiatives is directed towards bettering vaccine distribution, prices, access especially for those living in underserved regions.
  • Collaborative Research and Development: The increased cooperation between Pharmaceutical companies, research institutions as well as government agencies have propelled innovation regarding toxoid vaccines. Consequently, such alliances accelerate new vaccine development and enhance earlier versions of these products.
  • Vaccines Safety Focus: Therefore, ongoing research aims at improving the safety and efficacy profiles of toxoid vaccines. These studies also seek to provide knowledge about side effects associated with vaccinations while also enhancing overall immunization activities.

These recent changes are having a profound influence in the toxoid vaccine market through pushing on novelty, improving production as well as extending availability. This has been brought about by developments in vaccine technology and public health strategies thus leading to better disease prevention and improved health outcomes.

Strategic Growth Opportunities for Toxoid Vaccine Market

The toxoid vaccine market is experiencing numerous strategic growth opportunities across several applications. These opportunities are due to progress in vaccine technology, increased prevalence of diseases, and changing needs in public health.

  • Infectious Disease Prevention: Developing toxoid vaccines for infectious diseases such as diphtheria, tetanus, and pertussis presents significant growth opportunities. Expanding vaccine coverage and improving vaccine formulas against these conditions can result in a better public health situation while preventing outbreaks.
  • Pediatric Immunization: For the pediatric immunization program, there is a strong growth opportunity for toxoid vaccines. Streamlining immunization schedules for early childhood diseases by developing combination vaccines would address common childhood illnesses effectively and improve coverage.
  • Travel Health: There are growth opportunities by targeting travelers with toxoid vaccines focusing on particular regions or diseases prevalent among them. Creating vaccines that offer broad protection to international travelers can support global health initiatives and thus enhance their expected health outcomes.
  • Elderly Health: The elderly are at risk of diseases such as tetanus, which presents a potential market for the development of toxoid vaccines. These vaccines should be designed specifically for the older population to have disease prevention improvements and better health outcomes within this age bracket

As a result, these opportunities are responsible for the shaping of the toxoid vaccine market through stimulating innovation and extending its areas of application. Those firms that will effectively address them will benefit from market expansion as well as contribute to better public health.

Toxoid Vaccine Market Driver and Challenges

Various technological, economic, and regulatory factors affect the toxoid vaccine market. Knowing what propels and poses a problem in these is crucial to steer through the market while seeking business growth opportunities.

The factors responsible for driving the toxoid vaccine market include:

1. Advances in Technology: Improved adjuvants and delivery systems are contributing to the expansion of vaccine technology. These breakthroughs enhance the efficiency and safety of vaccines while addressing emerging public health priorities.

2. Increasing Disease Prevalence: The increasing prevalence of diseases like diphtheria and tetanus has led to a growing demand for toxoid vaccines. Consequently, it is important to develop efficient vaccines against these threats to public health and disease prevention.

3. Government Investment: Market growth is supported by heavy government spending on vaccine research, production, and public health programs. Thus, funding initiatives are designed to improve the accessibility, affordability, and coverage of vaccines.

4. Global Health Initiatives: International cooperation as well as healthcare initiatives have improved access to toxoid vaccines. This further includes programs that seek improving distribution methods for immunizations and tackling health disparities which contribute towards market development.

5. Vaccine Safety Emphasis: Research aimed at improving vaccine safety dictates the course market trends are taking today. Thus having safe and effective vaccines builds confidence among people about immunization thus promoting their uptake.

Challenges in the toxoid vaccine market are:

1. Exorbitant Development Expenses: The production of toxoid vaccines is associated with research, clinical trials, and manufacturing costs. The price can be prohibitive and hence limit market entry.

2. Regulatory Barriers: Vaccine development can be slowed down by strict regulatory requirements and approval processes. It may not be easy but it has to comply with safety standards.

3. Problems With Supply Chain: Anything that disrupts the supply chain for vaccines from raw material shortage to production delays will have an influence on vaccine availability and distribution.

The toxoid vaccine market is influenced by the advances in technology, increasing rates of diseases and large investment. However, to maintain the growth and stability of the market, there still exist a number of challenges that includes high cost of development, regulatory barriers as well as supply chain issues.

List of Toxoid Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies toxoid vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the toxoid vaccine companies profiled in this report include-

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Toxoid Vaccine by Segment

The study includes a forecast for the global toxoid vaccine by vaccine type, end use, and region.

Toxoid Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

  • Diphtheria, Tetanus, and Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
  • Tetanus, Diphtheria, and Pertussis (TDaP)
  • Others

Toxoid Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Centre
  • Governments Organization
  • Others

Toxoid Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Toxoid Vaccine Market

The toxoid vaccine industry has progressed significantly in major regions, supported by advancements in vaccine technology, disease management strategies, and public health programs. The recent developments seen in the United States, China, Germany, India, and Japan are a reflection of worldwide efforts towards increased toxoid vaccine effectiveness and accessibility with innovative responses to different health challenges.

  • United States: In the USA there have been breakthroughs such as combined toxic vaccines for diseases like diphtheria and tetanus. Innovations in vaccine formulations and delivery systems have improved the efficacy of vaccines while at the same time ensuring that patients adhere to prescribed dosages. Besides this, the US is also focusing on accessing public health programs and ensuring the availability of updated toxic vaccines nationwide.
  • China: China has made remarkable achievements in toxoid vaccine development for instance diphtheria tetanus pertussis. These include improving vaccine production capacity as well as carrying out clinical trials to boost the efficacy of vaccines. The Chinese government has invested heavily in vaccine research and public health infrastructure that would expand coverage of vaccination while tackling emerging health issues related to it.
  • Germany: Germany's toxoid vaccine research is progressing with a view to improving vaccine safety and efficacy. This has seen the introduction of new formulations and adjuvants aimed to improve immune responses. robustness of Germany's regulatory framework, which involves close cooperation between pharmaceutical companies and research institutions, supports innovative developments in toxoid vaccines.
  • India: Recent advances that have been made regarding the accessibility and affordability concerns surrounding toxoid vaccines in India have been an effort by various stakeholders. The country is increasing its ability to produce these vaccines as well as creating new ones for example tetanus and diphtheria. This has mainly been made possible through government initiatives as well as partnering with international organizations to ensure that more Indian population are immunized.
  • Japan: In Japan, there has been progress in toxoid vaccines aiming at improving vaccine formulation and safety issues. Recently, some of the advancements include studying new adjuvants and delivery systems for enhanced vaccine effectiveness. Toxoid vaccine development in Japan is driven by public health commitment that exist within both the government departments and also from collaboration between these agencies together with private sectors such as pharmacology firms.

Features of the Global Toxoid Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Toxoid vaccine market size by vaccine type, end use, and region in terms of value ($B).

Regional Analysis: Toxoid vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, end uses, and regions for the toxoid vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the toxoid vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the toxoid vaccine market size?

Answer: The global toxoid vaccine market is expected to reach an estimated $7.5 billion by 2030.

Q.2 What is the growth forecast for toxoid vaccine market?

Answer: The global toxoid vaccine market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the toxoid vaccine market?

Answer: The major drivers for this market are rising prevalence of infectious diseases, augmenting demand for vaccination in developing countries and, supportive initiatives by the government to encourage immunization.

Q4. What are the major segments for toxoid vaccine market?

Answer: The future of the toxoid vaccine market looks promising with opportunities in the hospital, specialty centre, and government organization markets.

Q5. Who are the key toxoid vaccine market companies?

Answer: Some of the key toxoid vaccine companies are as follows:

  • Bharat Biotech
  • Ceva
  • GlaxoSmithKline
  • Grifols
  • Zoetis
  • Sanofi
  • Merck & Co
  • Emergent Biosolutions
  • Integrated Biotherapeutics
  • Abbott

Q6. Which toxoid vaccine market segment will be the largest in the future?

Answer: Lucintel forecasts that DTaP is expected to witness the highest growth over the forecast period due to its growing usage among children to protect against the dangerous illnesses of diphtheria, tetanus, and pertussis.

Q7. In toxoid vaccine market, which region is expected to be the largest in the next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to the rapid population growth and the rising cases of infectious illnesses among people in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the toxoid vaccine market by vaccine type (diphtheria, tetanus, and pertussis (DTaP), diphtheria and tetanus (DT), tetanus, diphtheria, and pertussis (TDaP), and others), end use (hospitals, specialty centre, governments organization, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Toxoid Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Toxoid Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Toxoid Vaccine Market by Vaccine Type
    • 3.3.1: Diphtheria, Tetanus, and Pertussis (DTaP)
    • 3.3.2: Diphtheria and Tetanus (DT)
    • 3.3.3: Tetanus, Diphtheria, and Pertussis (TDaP)
    • 3.3.4: Others
  • 3.4: Global Toxoid Vaccine Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Specialty Centre
    • 3.4.3: Governments Organization
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Toxoid Vaccine Market by Region
  • 4.2: North American Toxoid Vaccine Market
    • 4.2.1: North American Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others 4.2.2: North American Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.3: European Toxoid Vaccine Market
    • 4.3.1: European Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.3.2: European Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.4: APAC Toxoid Vaccine Market
    • 4.4.1: APAC Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.4.2: APAC Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others
  • 4.5: ROW Toxoid Vaccine Market
    • 4.5.1: ROW Toxoid Vaccine Market by Vaccine Type: Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (TDaP), and Others
    • 4.5.2: ROW Toxoid Vaccine Market by End Use: Hospitals, Specialty Centre, Governments Organization, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Toxoid Vaccine Market by Vaccine Type
    • 6.1.2: Growth Opportunities for the Global Toxoid Vaccine Market by End Use
    • 6.1.3: Growth Opportunities for the Global Toxoid Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Toxoid Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Toxoid Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Toxoid Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bharat Biotech
  • 7.2: Ceva
    • 7.1.1: GlaxoSmithKline
  • 7.4: Grifols
  • 7.5: Zoetis
  • 7.6: Sanofi
  • 7.7: Merck & Co
  • 7.8: Emergent BioSolutions
  • 7.9: Integrated Biotherapeutics
  • 7.10: Abbott